Skip to content

Safety for Continnuous Intake of fungal Beta-Glucan polysaccharide and Beta-Glucan oligosaccharide in healthy volunteers

Clinical Safety Study for Continuous Intake of Beta-Glucan polysaccharide and Beta-Glucan oligosaccharide from Ophiocordyceps dipterigena BCC 2073 in healthy volunteers

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240622005
Enrollment
96
Registered
2024-06-22
Start date
2023-08-14
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy participants beta-Glucans Polysaccharides Oligosaccharides Fungi Randomized Controlled Trial Safety Dietary Supplements

Interventions

daily oral intake of 2000 mg of beta-glucan capsule once a day before breakfast for 12 weeks,daily oral intake of 2000 mg of beta-glucan capsule once a day before breakfast for 12 weeks,daily oral int
beta-glucan oligosachharides,beta-glucan polysachharides,placebo

Sponsors

Institute of Nutrition, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. 20-55 years old, 2. healthy with no systemic diseases, 3. BMI less than 30 kg/m2, 4. acceptable normal blood biochemical parameters (hemoglobin 11-16 gm/ dL for female or 12-18 gm/dL for male, white blood cells 4,000 to 10,000 cells/mm3, asting plasma glucose no more than 125 mg/dL, HbA1c no more than 5.8 percent, total cholesterol/ HDL ratio no more than 5.1, ALT no more than 60 U/L, eGFR at least 90 mL/min/ 1.73 m2), 5. acceptable normal blood pressure (diastolic pressure 60-90 mm Hg, systolic pressure 90-140 mm Hg), 6. normal heart rate (no more than 100 times/ min)

Exclusion criteria

Exclusion criteria: 1. History of COVID-19 infection or exposure, 2. History of allergy to Cordyceps or other herbs, 3. Unable to follow-up every 4 weeks, 4. Pregnant or plan to get pregnant within 3 months, 5. Regular consumption of drugs, herbs or dietary supplements, 6. Breastfeeding, 7. alcohol intake > 14 drinks per week for male or > 7 drinks per week for females and cannot refrain from alcohol intake during the study, 8. smoking > 10 cigarettes/day, 9. Bleeding problems e.g. idiopathic thrombocytopenia, 10. Having certain conditions not suitable to consume beta-glucans e.g. severe gastrointestinal diseases

Design outcomes

Primary

MeasureTime frame
symptoms related to the safety and tolerability of products 4, 8, 12, 14 weeks after intervention subject diary and interview,blood biochemical parameters (liver, kidney function, CBC, lipid profile, fasting blood sugar) 4, 8, 12, 14 weeks after intervention blood test ,body weight 4, 8, 12, 14 weeks after intervention weighing scale,urine parameters (color, pH, protein, WBC, RBC, bacteria, etc) 4, 8, 12, 14 weeks after intervention urinalysis,EKG 4, 8, 12, 14 weeks after intervention EKG

Secondary

MeasureTime frame
defecation frequency weekly subject diary ,stool consistency weekly Bristol stool scale

Countries

Thailand

Contacts

Public ContactDunyaporn Trachootham

Institute of Nutrition, Mahidol University

dunyaporn.tra@mahidol.edu66846953647

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026